ISIN | LU1334635189 |
---|---|
Valor Number | 30674050 |
Bloomberg Global ID | |
Fund Name | Crossfund Sicav-Crossinvest Healthcare Fund B CHF |
Fund Provider |
Crossinvest SA
Lugano, Switzerland Phone: +41 91 911 88 88 E-Mail: info@crossinvest.ch Web: www.crossinvest.ch |
Fund Provider | Crossinvest SA |
Representative in Switzerland |
FundPartner Solutions (Suisse) SA Genève 75 |
Distributor(s) |
FundPartner Solutions (Suisse) SA Genève 3 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The investment objective of the Sub‐Fund is to achieve a long term capital appreciation by pursuing sector focus exposure opportunities in companies involved in health and personal care. These companies could participate in the research, clinical development or commercialization of medicines, equipment or services for disease treatment or life style improvement. The investment focus will be on industry leaders that offer premium growth and/or profitability prospects, pipeline and valuation upside. The Sub‐Fund is actively managed. The Sub‐Fund has no benchmark index and is not managed in reference to a benchmark index. |
Peculiarities |
Current Price * | 117.55 CHF | 31.03.2025 |
---|---|---|
Previous Price * | 117.78 CHF | 28.03.2025 |
52 Week High * | 140.57 CHF | 30.08.2024 |
52 Week Low * | 115.41 CHF | 30.12.2024 |
NAV * | 117.55 CHF | 31.03.2025 |
Issue Price * | 117.55 CHF | 31.03.2025 |
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 68,193,912 | |
Unit/Share Assets *** | 11,755 | |
Trading Information SIX |
YTD Performance | +1.70% |
31.12.2024 - 31.03.2025
31.12.2024 31.03.2025 |
---|---|---|
1 month | -4.17% |
28.02.2025 - 31.03.2025
28.02.2025 31.03.2025 |
3 months | +1.70% |
31.12.2024 - 31.03.2025
31.12.2024 31.03.2025 |
6 months | -12.46% |
30.09.2024 - 31.03.2025
30.09.2024 31.03.2025 |
1 year | -10.44% |
02.04.2024 - 31.03.2025
02.04.2024 31.03.2025 |
2 years | -6.33% |
31.03.2023 - 31.03.2025
31.03.2023 31.03.2025 |
3 years | -16.20% |
31.03.2022 - 31.03.2025
31.03.2022 31.03.2025 |
5 years | +10.00% |
31.03.2020 - 31.03.2025
31.03.2020 31.03.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Novo Nordisk AS Class B | 5.43% | |
---|---|---|
Eli Lilly and Co | 4.63% | |
UnitedHealth Group Inc | 3.71% | |
AstraZeneca PLC | 3.70% | |
Thermo Fisher Scientific Inc | 3.09% | |
Roche Holding AG | 3.09% | |
Danaher Corp | 3.04% | |
Sanofi SA | 2.96% | |
Novartis AG Registered Shares | 2.82% | |
Abbott Laboratories | 2.77% | |
Last data update | 30.11.2024 |
TER | |
---|---|
TER date | |
Performance Fee *** | 15.00% |
PTR | |
Max. Management Fee *** | 1.80% |
Ongoing Charges *** | |
SRRI ***
|
|
SRRI date *** | 28.02.2025 |